Results 181 to 190 of about 90,630 (268)

Quantitative Model‐Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Milvexian, an activated factor XI inhibitor, is being evaluated in the LIBREXIA phase III program for the prevention of thrombotic events, including in patients with atrial fibrillation (LIBREXIA AF). To guide the selection of a phase III dose regimen for LIBREXIA AF, two main approaches were used: (1) population pharmacokinetics and exposure–response ...
Wangda Zhou   +12 more
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich   +5 more
wiley   +1 more source

Navigating Sustainability Challenges Through Innovation: Dynamic Capabilities in the Italian Wineries

open access: yesCorporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT As environmental pressures and corporate social responsibility demands intensify, organizations face growing pressure to adopt adaptive, sustainability‐oriented strategies. This challenge is especially relevant in globally significant industries such as wine production, which is economically and culturally vital in countries like Italy.
Leonardo Agnusdei   +2 more
wiley   +1 more source

The role of investment for poverty alleviation in Yogyakarta: Evidence from logit regression

open access: gold
Suripto Suripto   +4 more
openalex   +1 more source

Home - About - Disclaimer - Privacy